MEDANTA Global Health Q3 FY26 results (Oct–Dec 2025) and concall
Global Health (Medanta) delivered a strong operational performance in Q3 FY26, characterized by double-digit revenue growth and significant traction in international business. While consolidated margins were temporarily compressed by the initial ramp-up losses at the new Noida facility and a one-time labor code impact, the core mature and developing clusters continue to show high operating leverage. Management remains focused on brownfield expansions and specialized clinical programs to drive long-term value.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 15.8%, net profit down 38.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 665 | 812 | 803 | 882 | 926 +39% | 940 +16% |
| EBITDA | 150 | 202 | 195 | 195 | 193 +29% | 174 −14% |
| Net profit | 104 | 131 | 93 | 152 | 140 +35% | 80 −39% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
